Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

A Corrigendum to this article was published on 27 January 2016

This article has been updated

Abstract

On activation by receptors, the ubiquitously expressed class IA isoforms (p110α and p110β) of phosphatidylinositol-3-OH kinase (PI(3)K) generate lipid second messengers, which initiate multiple signal transduction cascades1,2,3,4,5. Recent studies have demonstrated specific functions for p110α in growth factor and insulin signalling6,7,8. To probe for distinct functions of p110β, we constructed conditional knockout mice. Here we show that ablation of p110β in the livers of the resulting mice leads to impaired insulin sensitivity and glucose homeostasis, while having little effect on phosphorylation of Akt, suggesting the involvement of a kinase-independent role of p110β in insulin metabolic action. Using established mouse embryonic fibroblasts, we found that removal of p110β also had little effect on Akt phosphorylation in response to stimulation by insulin and epidermal growth factor, but resulted in retarded cell proliferation. Reconstitution of p110β-null cells with a wild-type or kinase-dead allele of p110β demonstrated that p110β possesses kinase-independent functions in regulating cell proliferation and trafficking. However, the kinase activity of p110β was required for G-protein-coupled receptor signalling triggered by lysophosphatidic acid and had a function in oncogenic transformation. Most strikingly, in an animal model of prostate tumour formation induced by Pten loss, ablation of p110β (also known as Pik3cb), but not that of p110α (also known as Pik3ca), impeded tumorigenesis with a concomitant diminution of Akt phosphorylation. Taken together, our findings demonstrate both kinase-dependent and kinase-independent functions for p110β, and strongly indicate the kinase-dependent functions of p110β as a promising target in cancer therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mice with liver-specific deletion of p110β show resistance to insulin and intolerance of glucose.
Figure 2: Analyses of the effects of p110β deletion on cell growth and signalling.
Figure 3: Kinase activity of p110β contributes to transformation both in vitro and in vivo.

Similar content being viewed by others

Change history

References

  1. Vanhaesebroeck, B. & Waterfield, M. D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253, 239–254 (1999)

    Article  CAS  Google Scholar 

  2. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–365 (2001)

    Article  ADS  CAS  Google Scholar 

  3. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002)

    Article  CAS  Google Scholar 

  4. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606–619 (2006)

    Article  CAS  Google Scholar 

  5. Liu, Z. & Roberts, T. M. Human tumor mutants in the p110α subunit of PI3K. Cell Cycle 5, 675–677 (2006)

    Article  CAS  Google Scholar 

  6. Foukas, L. C. et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366–370 (2006)

    Article  ADS  CAS  Google Scholar 

  7. Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733–747 (2006)

    Article  CAS  Google Scholar 

  8. Zhao, J. J. et al. The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl Acad. Sci. USA 103, 16296–16300 (2006)

    Article  ADS  CAS  Google Scholar 

  9. Bader, A. G., Kang, S., Zhao, L. & Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nature Rev. Cancer 5, 921–929 (2005)

    Article  CAS  Google Scholar 

  10. Vanhaesebroeck, B. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535–602 (2001)

    Article  CAS  Google Scholar 

  11. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. & Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963–10968 (1999)

    Article  CAS  Google Scholar 

  12. Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome 13, 169–172 (2002)

    CAS  PubMed  Google Scholar 

  13. Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C. & Cantley, L. C. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25, 1596–1607 (2005)

    Article  CAS  Google Scholar 

  14. Shaulian, E., Zauberman, A., Ginsberg, D. & Oren, M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12, 5581–5592 (1992)

    Article  CAS  Google Scholar 

  15. Hazeki, O. et al. Activation of PI 3-kinase by G protein βγ subunits. Life Sci. 62, 1555–1559 (1998)

    Article  CAS  Google Scholar 

  16. Roche, S., Downward, J., Raynal, P. & Courtneidge, S. A. A function for phosphatidylinositol 3-kinase β (p85α-p110β) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction. Mol. Cell. Biol. 18, 7119–7129 (1998)

    Article  CAS  Google Scholar 

  17. Yart, A. et al. A function for phosphoinositide 3-kinase β lipid products in coupling βγ to Ras activation in response to lysophosphatidic acid. J. Biol. Chem. 277, 21167–21178 (2002)

    Article  CAS  Google Scholar 

  18. Nobukuni, T. et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl Acad. Sci. USA 102, 14238–14243 (2005)

    Article  ADS  CAS  Google Scholar 

  19. Shin, H. W. et al. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. J. Cell Biol. 170, 607–618 (2005)

    Article  CAS  Google Scholar 

  20. Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G. & Penichet, M. L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121, 144–158 (2006)

    Article  CAS  Google Scholar 

  21. Bellacosa, A. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995)

    Article  CAS  Google Scholar 

  22. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997)

    Article  CAS  Google Scholar 

  23. Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356–362 (1997)

    Article  CAS  Google Scholar 

  24. Ringel, M. D. et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 61, 6105–6111 (2001)

    CAS  PubMed  Google Scholar 

  25. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004)

    Article  CAS  Google Scholar 

  26. Zhao, J. J. et al. The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl Acad. Sci. USA 102, 18443–18448 (2005)

    Article  ADS  CAS  Google Scholar 

  27. Bader, A. G., Kang, S. & Vogt, P. K. Cancer-specific mutations in PIK3CA are oncogenic in vivo . Proc. Natl Acad. Sci. USA 103, 1475–1479 (2006)

    Article  ADS  CAS  Google Scholar 

  28. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005)

    Article  ADS  CAS  Google Scholar 

  29. Lesche, R. et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32, 148–149 (2002)

    Article  CAS  Google Scholar 

  30. Wu, X. et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61–69 (2001)

    Article  CAS  Google Scholar 

  31. Taniguchi, C. M. et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ. Cell Metab. 3, 343–353 (2006)

    Article  CAS  Google Scholar 

  32. Graner, E. et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5, 253–261 (2004)

    Article  CAS  Google Scholar 

  33. Sever, S., Damke, H. & Schmid, S. L. Dynamin:GTP controls the formation of constricted coated pits, the rate limiting step in clathrin-mediated endocytosis. J. Cell Biol. 150, 1137–1148 (2000)

    Article  CAS  Google Scholar 

  34. Emmert-Buck, M. R. et al. Laser capture microdissection. Science 274, 998–1001 (1996)

    Article  ADS  CAS  Google Scholar 

Download references

Acknowledgements

We thank C. D. Stiles and J. D. Iglehart for advice, and H. Wu for providing floxed PTEN mice. This work was supported by grants from the National Institutes of Health (M.L., T.M.R. and J.J.Z.,), the Department of Defense for Cancer Research (J.J.Z.), the V Foundation (J.J.Z.) and the Claudia Barr Program (J.J.Z.). In compliance with Harvard Medical School guidelines, we disclose the consulting relationships: Novartis Pharmaceuticals, Inc. (M.L., T.M.R. and J.J.Z.).

Author Contributions Z.L., S.Z. and S.L. generated the floxed p110β mouse. S.J. carried out mouse tumorigenesis studies. Z.L and S.Z. performed MEF studies. P.L. performed in vivo metabolic studies. L.Z. performed transferrin uptake assays. J.Z. assisted in focus formation and BrdU incorporation experiments. S.S. and M.L. performed and interpreted pathological analyses of mouse prostate tumors. T.M.R. and J.J.Z. supervised the research, interpreted the data and wrote the paper. S.J., Z.L., S.Z., P.L., L.Z., S.L. and M.L. participated in the writing of the paper.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Thomas M. Roberts or Jean J. Zhao.

Supplementary information

Supplementary Figures

The file contains Supplementary Figures 1-12 and Legends. The Supplementary Figures and Legends show additional data to support the kinase-dependent and -independent functions of PI3K-p110:β in cell growth, metabolism and tumorigenesis. (PDF 2415 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jia, S., Liu, Z., Zhang, S. et al. Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis. Nature 454, 776–779 (2008). https://doi.org/10.1038/nature07091

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature07091

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing